Sera miR-34a, miR-29b and miR-181c as potential novel diagnostic biomarker panel for Alzheimers in the Egyptian population

• Published in: Experimental gerontology 2022-11, Vol.169, p.111961-111961, Article 111961
• Main Authors: Abuelezz, Nermeen Z., Nasr, Fayza Eid, Abdel Aal, Waleed M., Molokhia, Tarek, Zaky, Amira
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - diagnosis; Alzheimer Disease - genetics; Alzheimer's; Amyloid beta-Peptides; Biomarker; Biomarkers; Diagnosis; Egypt; Egyptian population; Humans; MicroRNAs; miRNA; Neurodegeneration; Tumor Necrosis Factor-alpha
• ISSN: 0531-5565; 1873-6815
• DOI: 10.1016/j.exger.2022.111961

Till date, there is an obvious obscurity of specific and early diagnostic biomarkers for Alzheimer's disease (AD). The promising diagnostic potential of serum miRNAs is increasingly emerging; however, rare miRNAs data originates from middle and low-income countries to provide proper validation in these highly affected populations. This study evaluated the diagnostic value of serum miR-34a, miR-29b and miR-181c in Egyptian AD patients. Expression levels of serum miR-34a, miR-29b and miR-181c were determined using quantitative real time PCR in AD patients versus healthy controls. Amyloid Beta 42 (Aβ42), Phosphorylated Tau (p-Tau) and TNF-α levels were also detected as distinctive AD markers. We further explored the correlation between miRNAs levels and Mini mental state examination (MMSE) scores. Finally, we conducted logistic regression and ROC curve analyses to evaluate the diagnostic values of the measured parameters. Sera miR-34a, miR-29b and miR-181c were significantly downregulated in AD patients and this decrease was associated with cognitive decline. AD patients manifested significant elevation of Aβ42, pTau and TNF-α levels. The measured miRNAs showed good AD diagnostic value solely and when used together (AUC = 0.77, 95 % C·I. 0.62–0.93 at p